Download PDF
Dtsch Med Wochenschr 2020; 145(04): 216-218
DOI: 10.1055/a-1005-0836
Aktuell publiziert
© Georg Thieme Verlag KG Stuttgart · New York

Stellenwert von Serelaxin in der Therapie der akuten Herzinsuffizienz

Further Information

Publication History

Publication Date:
18 February 2020 (online)

Also available at
    Permissions and Reprints

Serelaxin ist eine rekombinante Form von humanem Relaxin-2. Das vasodilatierende Hormon ist beteiligt an kardiovaskulären und renalen Adaptationsvorgängen während der Schwangerschaft und besitzt antifibrotische, antiinflammatorische und gegenüber Endorganen protektive Eigenschaften. Bisherige Untersuchungen lassen vermuten, dass eine Behandlung mit Serelaxin bei akuter Herzinsuffizienz Symptome lindern und Behandlungsergebnisse verbessern kann.
 

  • Literatur

  • 1 Kristensen SL, Jhund PS, Køber L. et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. Eur J Heart Fail 2015; 17: 169-176
    CrossrefPubMedGoogle Scholar
  • 2 Solomon SD, Dobson J, Pocock S. et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116: 1482-1487
    CrossrefPubMedGoogle Scholar
  • 3 Ahmed A, Allman RM, Fonarow GC. et al. Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail 2008; 14: 211-218 . doi:10.1016/j.cardfail.2007.12.001
    CrossrefPubMedGoogle Scholar
  • 4 Harjola VP, Mullens W, Banaszewski M. et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2017; 19: 821-836 . doi:10.1002/ejhf.872.5
    CrossrefPubMedGoogle Scholar
  • 5 Metra M, Cotter G, Davison BA. et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013; 61: 196-206 . doi:10.1016/j.jacc.2012.11.005
    CrossrefPubMedGoogle Scholar
  • 6 Maggioni AP, López-Sendón J, Nielsen OW. et al. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU. Eur J Heart Fail 2019; 21: 322-333 . doi:10.1002/ejhf.1368
    CrossrefPubMedGoogle Scholar